Damora Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
-- CLARITY-101 Phase 1/1b clinical trial initiated and cleared by multiple global regulatory authorities, including the U.S. Food and Drug Administration (FDA) -- -- New preclinical data highlighting DMR-001’s potentially best-in-class pan-mutant CALR (mutCALR) activity to be presented at the American Society of Hematology (ASH) 2026 Annual Meeting --
Covered in this story
Call it yourself
No calls on $ASH yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Ashland →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.